Compare · BJDX vs MDLN
BJDX vs MDLN
Side-by-side comparison of Bluejay Diagnostics Inc. (BJDX) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BJDX and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $50.91B, about 47764.6x BJDX ($1.1M).
- Over the past year, BJDX is down 83.5% and MDLN is down 4.8% - MDLN leads by 78.7 points.
- BJDX has been more active in the news (9 items in the past 4 weeks vs 5 for MDLN).
- MDLN has more recent analyst coverage (25 ratings vs 1 for BJDX).
- Company
- Bluejay Diagnostics Inc.
- Medline Inc.
- Price
- $1.03-10.00%
- $38.78+3.02%
- Market cap
- $1.1M
- $50.91B
- 1M return
- -67.61%
- +7.57%
- 1Y return
- -83.52%
- -4.83%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2025
- News (4w)
- 9
- 5
- Recent ratings
- 1
- 25
Bluejay Diagnostics Inc.
Bluejay Diagnostics, Inc., an in-vitro diagnostic company, develops, manufactures, and markets minimally invasive point-of-care (POC) diagnostics tests and devices for infectious disease, inflammation, and oncology markets in the United States. It is developing Symphony biomarker detection platform for the detection of sepsis, cancer, cardiac ishcemia, and congestive heart failure. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. It has a collaboration agreement with Toray Industries, Inc. to develop a point of care test for covid-19 patient triage; and a research and development agreement with Naval Medical Research Center to develop lateral flow rapid test for diagnosis of various tick-borne diseases, including Lyme disease. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Latest BJDX
- Bluejay Diagnostics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 4 filed by Large owner Bank Of America Corp /De/
- New insider Bank Of America Corp /De/ claimed ownership of 8 shares (SEC Form 3)
- Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study
- Large owner Hrt Financial Lp bought $96,711 worth of shares (64,047 units at $1.51) and sold $48,913 worth of shares (34,938 units at $1.40), increasing direct ownership by 46% to 92,055 units (SEC Form 4)
- New insider Hrt Financial Lp claimed ownership of 126,993 shares (SEC Form 3)
- SEC Form 4 filed by Large owner Bank Of America Corp /De/
- New insider Bank Of America Corp /De/ claimed ownership of 8 shares (SEC Form 3)
- SEC Form EFFECT filed by Bluejay Diagnostics Inc.
- SEC Form 424B3 filed by Bluejay Diagnostics Inc.
Latest MDLN
- Medline strengthens California distribution network with new 1 million-square-foot facility in Perris
- Medline Inc. filed SEC Form 8-K: Leadership Update
- Medline announces Prime Vendor agreement with Allina Health
- Securing new 1.6-plus million square feet of new space after fire, Medline leases two large distribution centers in Northern California
- Medline to report second quarter 2026 results on August 5, 2026
- Officer Abrams William J covered exercise/tax liability with 1,308 shares, decreasing direct ownership by 7% to 16,546 units (SEC Form 4)
- Chief Human Resources Officer Shryock Christopher P covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Operating Officer Miller Stephen L covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Legal Officer Liberman Alexander M. covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Product Officer Laabs Amanda H. covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)